APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Opioid Receptor Agonist Market Outlook and Growth Opportunities 2026

30 December 2025196 pages

Choose your research edition.

Industry ResearchOpioid Receptor Agonist Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Receptor Agonist Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Receptor Agonist Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Receptor Agonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Opioid Receptor Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Opioid Receptor Agonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Opioid Receptor Agonist market include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Receptor Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Receptor Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Receptor Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Receptor Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Receptor Agonist Segment by Company

Allergan

DAIICHI SANKYO COMPANY

Endo Pharmaceuticals

Fresenius Kabi

Hikma Pharmaceuticals

Indivior

Mylan N.V.

Piramal Critical Care

Purdue Pharma

Sun Pharmaceutical Industries

Tris Pharma

US WorldMeds

Pfizer

Johnson & Johnson

Teva Pharmaceutical Industries

Opioid Receptor Agonist Segment by Type

Morphine

Codeine

Fentanyl

Others

Opioid Receptor Agonist Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Opioid Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Opioid Receptor Agonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Opioid Receptor Agonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioid Receptor Agonist significant trends, drivers, influence factors in global and regions.

6. To analyze Opioid Receptor Agonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Receptor Agonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid Receptor Agonist industry.

Chapter 3: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Opioid Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Opioid Receptor Agonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioid Receptor Agonist Industry Trends Table 2. Opioid Receptor Agonist Industry Drivers Table 3. Opioid Receptor Agonist Industry Opportunities and Challenges Table 4. Opioid Receptor Agonist Industry Restraints Table 5. Global Opioid Receptor Agonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioid Receptor Agonist Revenue Share by Company (2021-2026) Table 7. Global Opioid Receptor Agonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Opioid Receptor Agonist Sales Volume Share by Company (2021-2026) Table 9. Global Opioid Receptor Agonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Opioid Receptor Agonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global Opioid Receptor Agonist Key Company Manufacturing Base & Headquarters Table 12. Global Opioid Receptor Agonist Company, Product Type & Application Table 13. Global Opioid Receptor Agonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Morphine Table 18. Significant Companies of Codeine Table 19. Significant Companies of Fentanyl Table 20. Significant Companies of Others Table 21. Global Opioid Receptor Agonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Opioid Receptor Agonist Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Opioid Receptor Agonist Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Opioid Receptor Agonist Sales Volume Share by Type (2021-2026) Table 25. Global Opioid Receptor Agonist Sales Volume Share by Type (2027-2032) Table 26. Global Opioid Receptor Agonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Opioid Receptor Agonist Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Opioid Receptor Agonist Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Opioid Receptor Agonist Sales Value Share by Type (2021-2026) Table 30. Global Opioid Receptor Agonist Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Retail Pharmacy Table 32. Significant Companies of Online Pharmacy Table 33. Significant Companies of Hospital Pharmacy Table 34. Global Opioid Receptor Agonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Opioid Receptor Agonist Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Opioid Receptor Agonist Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Opioid Receptor Agonist Sales Volume Share by Application (2021-2026) Table 38. Global Opioid Receptor Agonist Sales Volume Share by Application (2027-2032) Table 39. Global Opioid Receptor Agonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Opioid Receptor Agonist Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Opioid Receptor Agonist Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Opioid Receptor Agonist Sales Value Share by Application (2021-2026) Table 43. Global Opioid Receptor Agonist Sales Value Share by Application (2027-2032) Table 44. Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Opioid Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 46. Global Opioid Receptor Agonist Sales Market Share by Region (2021-2026) Table 47. Global Opioid Receptor Agonist Sales by Region (2027-2032) & (K Units) Table 48. Global Opioid Receptor Agonist Sales Market Share by Region (2027-2032) Table 49. Global Opioid Receptor Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Opioid Receptor Agonist Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Opioid Receptor Agonist Sales Value Share by Region (2021-2026) Table 52. Global Opioid Receptor Agonist Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Opioid Receptor Agonist Sales Value Share by Region (2027-2032) Table 54. Global Opioid Receptor Agonist Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Opioid Receptor Agonist Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Opioid Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Opioid Receptor Agonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 59. Global Opioid Receptor Agonist Sales Market Share by Country (2021-2026) Table 60. Global Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 61. Global Opioid Receptor Agonist Sales Market Share by Country (2027-2032) Table 62. Global Opioid Receptor Agonist Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Opioid Receptor Agonist Sales Value Market Share by Country (2021-2026) Table 64. Global Opioid Receptor Agonist Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Opioid Receptor Agonist Sales Value Market Share by Country (2027-2032) Table 66. Allergan Company Information Table 67. Allergan Business Overview Table 68. Allergan Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Allergan Opioid Receptor Agonist Product Portfolio Table 70. Allergan Recent Development Table 71. DAIICHI SANKYO COMPANY Company Information Table 72. DAIICHI SANKYO COMPANY Business Overview Table 73. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio Table 75. DAIICHI SANKYO COMPANY Recent Development Table 76. Endo Pharmaceuticals Company Information Table 77. Endo Pharmaceuticals Business Overview Table 78. Endo Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 80. Endo Pharmaceuticals Recent Development Table 81. Fresenius Kabi Company Information Table 82. Fresenius Kabi Business Overview Table 83. Fresenius Kabi Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Fresenius Kabi Opioid Receptor Agonist Product Portfolio Table 85. Fresenius Kabi Recent Development Table 86. Hikma Pharmaceuticals Company Information Table 87. Hikma Pharmaceuticals Business Overview Table 88. Hikma Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 90. Hikma Pharmaceuticals Recent Development Table 91. Indivior Company Information Table 92. Indivior Business Overview Table 93. Indivior Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Indivior Opioid Receptor Agonist Product Portfolio Table 95. Indivior Recent Development Table 96. Mylan N.V. Company Information Table 97. Mylan N.V. Business Overview Table 98. Mylan N.V. Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Mylan N.V. Opioid Receptor Agonist Product Portfolio Table 100. Mylan N.V. Recent Development Table 101. Piramal Critical Care Company Information Table 102. Piramal Critical Care Business Overview Table 103. Piramal Critical Care Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Piramal Critical Care Opioid Receptor Agonist Product Portfolio Table 105. Piramal Critical Care Recent Development Table 106. Purdue Pharma Company Information Table 107. Purdue Pharma Business Overview Table 108. Purdue Pharma Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Purdue Pharma Opioid Receptor Agonist Product Portfolio Table 110. Purdue Pharma Recent Development Table 111. Sun Pharmaceutical Industries Company Information Table 112. Sun Pharmaceutical Industries Business Overview Table 113. Sun Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 115. Sun Pharmaceutical Industries Recent Development Table 116. Tris Pharma Company Information Table 117. Tris Pharma Business Overview Table 118. Tris Pharma Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Tris Pharma Opioid Receptor Agonist Product Portfolio Table 120. Tris Pharma Recent Development Table 121. US WorldMeds Company Information Table 122. US WorldMeds Business Overview Table 123. US WorldMeds Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. US WorldMeds Opioid Receptor Agonist Product Portfolio Table 125. US WorldMeds Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Pfizer Opioid Receptor Agonist Product Portfolio Table 130. Pfizer Recent Development Table 131. Johnson & Johnson Company Information Table 132. Johnson & Johnson Business Overview Table 133. Johnson & Johnson Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Johnson & Johnson Opioid Receptor Agonist Product Portfolio Table 135. Johnson & Johnson Recent Development Table 136. Teva Pharmaceutical Industries Company Information Table 137. Teva Pharmaceutical Industries Business Overview Table 138. Teva Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 140. Teva Pharmaceutical Industries Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Opioid Receptor Agonist Distributors List Table 144. Opioid Receptor Agonist Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Opioid Receptor Agonist Product Image Figure 2. Global Opioid Receptor Agonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global Opioid Receptor Agonist Sales (2021-2032) & (K Units) Figure 5. Global Opioid Receptor Agonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Opioid Receptor Agonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Morphine Image Figure 10. Codeine Image Figure 11. Fentanyl Image Figure 12. Others Image Figure 13. Global Opioid Receptor Agonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Opioid Receptor Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Opioid Receptor Agonist Sales Volume Share by Type (2021-2032) Figure 16. Global Opioid Receptor Agonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Opioid Receptor Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Opioid Receptor Agonist Sales Value Share by Type (2021-2032) Figure 19. Retail Pharmacy Image Figure 20. Online Pharmacy Image Figure 21. Hospital Pharmacy Image Figure 22. Global Opioid Receptor Agonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Opioid Receptor Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Opioid Receptor Agonist Sales Volume Share by Application (2021-2032) Figure 25. Global Opioid Receptor Agonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Opioid Receptor Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Opioid Receptor Agonist Sales Value Share by Application (2021-2032) Figure 28. Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Opioid Receptor Agonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Opioid Receptor Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Opioid Receptor Agonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 33. North America Opioid Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Opioid Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Opioid Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 39. South America Opioid Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Opioid Receptor Agonist Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Opioid Receptor Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Opioid Receptor Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Opioid Receptor Agonist Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Opioid Receptor Agonist Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Morphine
  • Codeine
  • Fentanyl
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Allergan
  • DAIICHI SANKYO COMPANY
  • Endo Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Indivior
  • Mylan N.V.
  • Piramal Critical Care
  • Purdue Pharma
  • Sun Pharmaceutical Industries
  • Tris Pharma
  • US WorldMeds
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid Receptor Agonist Sales Value (2021-2032)
  4. 1.2.2 Global Opioid Receptor Agonist Sales Volume (2021-2032)
  5. 1.2.3 Global Opioid Receptor Agonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Opioid Receptor Agonist Market Dynamics
  1. 2.1 Opioid Receptor Agonist Industry Trends
  2. 2.2 Opioid Receptor Agonist Industry Drivers
  3. 2.3 Opioid Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 Opioid Receptor Agonist Industry Restraints
3 Opioid Receptor Agonist Market by Company
  1. 3.1 Global Opioid Receptor Agonist Company Revenue Ranking in 2025
  2. 3.2 Global Opioid Receptor Agonist Revenue by Company (2021-2026)
  3. 3.3 Global Opioid Receptor Agonist Sales Volume by Company (2021-2026)
  4. 3.4 Global Opioid Receptor Agonist Average Price by Company (2021-2026)
  5. 3.5 Global Opioid Receptor Agonist Company Ranking (2024-2026)
  6. 3.6 Global Opioid Receptor Agonist Company Manufacturing Base and Headquarters
  7. 3.7 Global Opioid Receptor Agonist Company Product Type and Application
  8. 3.8 Global Opioid Receptor Agonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Opioid Receptor Agonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Opioid Receptor Agonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Opioid Receptor Agonist Market by Type
  1. 4.1 Opioid Receptor Agonist Type Introduction
  2. 4.1.1 Morphine
  3. 4.1.2 Codeine
  4. 4.1.3 Fentanyl
  5. 4.1.4 Others
  6. 4.2 Global Opioid Receptor Agonist Sales Volume by Type
  7. 4.2.1 Global Opioid Receptor Agonist Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioid Receptor Agonist Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Opioid Receptor Agonist Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Opioid Receptor Agonist Sales Value by Type
  11. 4.3.1 Global Opioid Receptor Agonist Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Opioid Receptor Agonist Sales Value by Type (2021-2032)
  13. 4.3.3 Global Opioid Receptor Agonist Sales Value Share by Type (2021-2032)
5 Opioid Receptor Agonist Market by Application
  1. 5.1 Opioid Receptor Agonist Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Opioid Receptor Agonist Sales Volume by Application
  6. 5.2.1 Global Opioid Receptor Agonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Receptor Agonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Opioid Receptor Agonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Opioid Receptor Agonist Sales Value by Application
  10. 5.3.1 Global Opioid Receptor Agonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Receptor Agonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global Opioid Receptor Agonist Sales Value Share by Application (2021-2032)
6 Opioid Receptor Agonist Regional Sales and Value Analysis
  1. 6.1 Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Receptor Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Receptor Agonist Sales by Region: 2021-2026
  4. 6.2.2 Global Opioid Receptor Agonist Sales by Region (2027-2032)
  5. 6.3 Global Opioid Receptor Agonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Opioid Receptor Agonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global Opioid Receptor Agonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global Opioid Receptor Agonist Sales Value by Region (2027-2032)
  9. 6.5 Global Opioid Receptor Agonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Opioid Receptor Agonist Sales Value (2021-2032)
  12. 6.6.2 North America Opioid Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Opioid Receptor Agonist Sales Value (2021-2032)
  15. 6.7.2 Europe Opioid Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Opioid Receptor Agonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Opioid Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Opioid Receptor Agonist Sales Value (2021-2032)
  21. 6.9.2 South America Opioid Receptor Agonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Opioid Receptor Agonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Opioid Receptor Agonist Sales Value Share by Country, 2025 VS 2032
7 Opioid Receptor Agonist Country-level Sales and Value Analysis
  1. 7.1 Global Opioid Receptor Agonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioid Receptor Agonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Opioid Receptor Agonist Sales by Country (2021-2032)
  4. 7.3.1 Global Opioid Receptor Agonist Sales by Country (2021-2026)
  5. 7.3.2 Global Opioid Receptor Agonist Sales by Country (2027-2032)
  6. 7.4 Global Opioid Receptor Agonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global Opioid Receptor Agonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global Opioid Receptor Agonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Opioid Receptor Agonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Opioid Receptor Agonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Opioid Receptor Agonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Opioid Receptor Agonist Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 DAIICHI SANKYO COMPANY
  8. 8.2.1 DAIICHI SANKYO COMPANY Company Information
  9. 8.2.2 DAIICHI SANKYO COMPANY Business Overview
  10. 8.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
  12. 8.2.5 DAIICHI SANKYO COMPANY Recent Developments
  13. 8.3 Endo Pharmaceuticals
  14. 8.3.1 Endo Pharmaceuticals Company Information
  15. 8.3.2 Endo Pharmaceuticals Business Overview
  16. 8.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  18. 8.3.5 Endo Pharmaceuticals Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 Hikma Pharmaceuticals
  26. 8.5.1 Hikma Pharmaceuticals Company Information
  27. 8.5.2 Hikma Pharmaceuticals Business Overview
  28. 8.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  30. 8.5.5 Hikma Pharmaceuticals Recent Developments
  31. 8.6 Indivior
  32. 8.6.1 Indivior Company Information
  33. 8.6.2 Indivior Business Overview
  34. 8.6.3 Indivior Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Indivior Opioid Receptor Agonist Product Portfolio
  36. 8.6.5 Indivior Recent Developments
  37. 8.7 Mylan N.V.
  38. 8.7.1 Mylan N.V. Company Information
  39. 8.7.2 Mylan N.V. Business Overview
  40. 8.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
  42. 8.7.5 Mylan N.V. Recent Developments
  43. 8.8 Piramal Critical Care
  44. 8.8.1 Piramal Critical Care Company Information
  45. 8.8.2 Piramal Critical Care Business Overview
  46. 8.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
  48. 8.8.5 Piramal Critical Care Recent Developments
  49. 8.9 Purdue Pharma
  50. 8.9.1 Purdue Pharma Company Information
  51. 8.9.2 Purdue Pharma Business Overview
  52. 8.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
  54. 8.9.5 Purdue Pharma Recent Developments
  55. 8.10 Sun Pharmaceutical Industries
  56. 8.10.1 Sun Pharmaceutical Industries Company Information
  57. 8.10.2 Sun Pharmaceutical Industries Business Overview
  58. 8.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  60. 8.10.5 Sun Pharmaceutical Industries Recent Developments
  61. 8.11 Tris Pharma
  62. 8.11.1 Tris Pharma Company Information
  63. 8.11.2 Tris Pharma Business Overview
  64. 8.11.3 Tris Pharma Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
  66. 8.11.5 Tris Pharma Recent Developments
  67. 8.12 US WorldMeds
  68. 8.12.1 US WorldMeds Company Information
  69. 8.12.2 US WorldMeds Business Overview
  70. 8.12.3 US WorldMeds Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
  72. 8.12.5 US WorldMeds Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Johnson & Johnson
  80. 8.14.1 Johnson & Johnson Company Information
  81. 8.14.2 Johnson & Johnson Business Overview
  82. 8.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
  84. 8.14.5 Johnson & Johnson Recent Developments
  85. 8.15 Teva Pharmaceutical Industries
  86. 8.15.1 Teva Pharmaceutical Industries Company Information
  87. 8.15.2 Teva Pharmaceutical Industries Business Overview
  88. 8.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  90. 8.15.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Receptor Agonist Value Chain Analysis
  2. 9.1.1 Opioid Receptor Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Receptor Agonist Sales Mode & Process
  6. 9.2 Opioid Receptor Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Receptor Agonist Distributors
  9. 9.2.3 Opioid Receptor Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst